Essential Premium

CTAs Suffer June Setback as Commodity Trends Unravel

Losses in metals and energy weighed on many managed futures funds, though top performers including Mulvaney and Drury remain up sharply in 2026.

Hedgies Eye Three Biopharma IPOs

A number of prominent hedge funds hope to duplicate the success of the most recent biopharma offerings.

Sponsored

Stagflation: Risks and Opportunities in Global Equities

Greenlight’s Flat June Masks Wild Swings Beneath the Surface

David Einhorn’s hedge fund gained just 20 basis points in June, but huge advances and steep declines among several of its largest holdings told a far more dramatic story.

Related Content

Hedge Funds Have a Reputation for Ruthlessness. Dmitry Balyasny Took a Different Approach.

Michelle Celarier

Famed Hedge Fund Firm CQS Is Surviving — But Not Because of Its Hedge Funds

Amanda Cantrell

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram